This company may have a cure for blindness. The FDA
holds special meeting to determine fast-track approval.
Trading halts.
If you buy this company on the cheap now - you could
potentially make 375% gains as the volume returns
after Labor Day�
Dear Friend,
Let me introduce myself. My name is Christian DeHaemer.
I've been working and investing on the cutting edge of
technology for more than eight years. In that time I've made
my readers are great deal of money trading on new
technology.
Right now is by far the best opportunity I've ever seen. It's
like buying AOL in 1996 at $0.53 and selling it at the top at
$93.
I'm not just whistling Dixie. My readers have gotten in early
on every new wave of high-tech investment. From the rise of
the Internet, to the mapping of human DNA, to the
emergence of nanotechnology - we've been there making
money.
In fact, from its inception in November 2000 to July 2004,
my VIP trading service has generated total gains of
3,684%!
That comes out to more than 1,053% every year!
And I get that number simply by adding up the winners and
subtracting the losers. The list is long and profitable: 73%
from Capstone, 206% from Navisite, 67% from Intertrust,
64% from Lexar, another 206% from Kana Software�
What's the next big technology that's going to make early
investors rich? There is a small and growing group of people
who believe that this is the last generation that will be
constrained by historical human problems.
These people call themselves "transhumanists." They think
that the technology will soon arrive that will enable humans
to be stronger, smarter, healthier and live up to twice as long
as today. And after looking at the evidence, I believe them.
Take a look�
Stories like these are commonplace:
"�stem cell therapy and biomolecular technology could
allow us to regenerate organs and transplant new ones as
needed, much like giving a car a tune-up or an oil change."
--ABC Online
"Computer intelligence will surpass human intelligence this
year."
--BBC
"Drugs that used to seem like the stuff of science fiction
could transform athletes into superhuman creatures�"
--San Jose Mercury News
And I'm not even talking about the astonishing science that is
now commonplace. Things like cloning, DNA mapping,
designer babies, nanotech molecular manipulation, bionic
limbs, or even laser eye treatment.
No more aging!
You could be among the last generation that will die a so-
called "natural death" or, if you're lucky, you may be in the
first generation that lives to be 150.
One of the chief causes of aging is mutations in
mitochondrial DNA. Aubrey de Grey of Cambridge
University believes that scientists can use the attributes of
nuclear DNA - which doesn't mutate - to transform
mitochondrial DNA and slowdown the aging process.
De Grey says that there is a "50-50 chance of effectively
reversing aging in 25 years."
You can make a fortune by investing in the same companies
that will save your life.
Red Zone VIP has a long history of detecting companies like
these. But it doesn't end there. That's why subscribers are
thrilled with the service. Here's what some happy investors
have to say about it�
"I sold AutoLiv today for a 65% profit. Thanks for the
recommendation both in and out."
--W.S.
"I purchased 3 calls on 12/30/03 at $1.00 and sold them on
1/14/04 for $4.70. I'm not a big trader, but try to buy as
many recommendations as I can with my limited funds.
Thanks for helping me make some money on this one."
--R.J.
"Great call on HRB - I got out yesterday with a 51% gain in
less than one and a half weeks. Keep up the great work.
Never had it so good so fast."
--R.M.
But I'm not here to brag about the past. I want to tell you
about the most exciting opportunity since the dawn of
mankind - literally.
We've found seven companies that are working to create the
"superhuman" of tomorrow. They are involved in every
aspect of the "transhuman" project� from creating new
organs, to finding a cure for Alzheimer's, to drugs that
manipulate hormone antibodies and increase strength, to
implantable microchips and silicone nanotech solutions.
The first of these seven stocks is on the launch pad and the
countdown to blastoff has begun.
This can't wait - trading will resume next week.
I don't have time to tell you about all seven of these
tremendous opportunities today. I have a pressing need to tell
you about a company that may have the cure for macular
degeneration. As I write this trading, has halted pending an
FDA meeting on fast-track approval for this treatment. Fast-
track approval would almost certainly trigger a higher stock
price.
For those who don't know, macular degeneration is a disease
wherein the light-sensing cells of the eye mysteriously
malfunction and over time cease to work. Victims lose all but
their peripheral vision. This generally affects people over 60
years old - the fastest growing portion of our population.
Seeing profits, saving sight.
You may not have problems with your eyesight, but chances
are you know someone who does. In the US alone, there are
more than 1.6 million people suffering from macular
degeneration, with about 200,000 new cases diagnosed every
year. If approved, this would be the company's first product
on the market. It will be co-marketed with Pfizer - a $244
billion company.
Right now, QLT and Novartis sell a product called Visudyne
that is the only approved treatment for "wet macular
degeneration," the smallest of the three types of the disease.
The little-known company I'm talking about is trying to get
approval to treat all three types of the disease, which could
help it realize about US$1 billion a year in sales. Obviously,
if this happens, it will not only improve the quality of life for
millions of people but also make a ton of money for those
who invest early as the stock goes through the roof.
Emergency meeting of the FDA.
Recent volume surges coupled with a buy signal from my
proprietary Tri-Directional Indicator suggest that the FDA
will grant fast-track approval.
You don't want to miss out. Put Red Zone VIP to work for
you. Visit this link for the Full Report:
http://www.agora-inc.com/reports/TRV/WTRVE801/
Sincerely,
Christian DeHaemer
Founder, Red Zone VIP
P.S. Give Red Zone VIP a risk-free trial today, and you'll get
Three Premium Trading Services� Red Zone Profits, EVS,
and Red Zone VIP� all for one low price. But this
opportunity is limited: first come, first served. No
exceptions! So please hurry. Here's where to learn all the
details about the service:
http://www.agora-inc.com/reports/TRV/WTRVE801/
===========================================
Keep the e-Dispatch coming to your mailbox!
If you enjoy reading the e-Dispatch, help us out by
"white-listing" our service... before delivery is interrupted.
You can find the details here:
http://www.youreletters.com/t/52758/3785361/134/56/
A big thanks in advance from your faithful e-Dispatch team.
===========================================
Now made available for e-Dispatch Readers Only!
Visit the 247profits e-Dispatch Blog. We update it daily.
It just another way for you to access our insights and
addictive stock market commentary.
To access the blog, visit:
http://www.youreletters.com/t/52758/3785361/367/56/
***********************************************
**NOTE TO AOL AND COMPUSERVE USERS: Please cut and paste the
links into your browser to access our special reports and other
offers.**
SPECIAL OFFER: As another 247profits e-Dispatch Membership
benefit, you have the opportunity to receive a FREE two-week
subscription to Investor's Business Daily.
10 FREE issues of Investor's Business Daily, the daily newspaper
for self-directed investors. Every issue of IBD includes stock
tables with IBD's exclusive SmartSelect Ratings, coverage of
institutional buying trends and 42 charts of top-rated stocks
currently advancing.
Here's where you can sign up:
http://www.youreletters.com/t/52758/3785361/391/56/
***********************************************
Copyright � 2004 by Taipan Group LLC. All rights reserved. The
Taipan Group's 247profits e-Dispatch is sent daily to a select
group of investors who share the courage and foresight to stay
ahead of today's markets. The Taipan Group unites the
stock-picking talents of several analysts and editors. We
publish a variety of monthly print newsletters, weekly and daily
trading alerts, and information services. Each of the services
is based on individual trading/investment philosophies or
vehicles and specific investment approaches.
Please note: It's not our intention to send email to anyone who
doesn't want it. If you would like to remove yourself from this
mailing list, please see the instructions at the
bottom of this message.
For more about us, and a summary of our editorial policy, please
read
http://www.youreletters.com/t/52758/3785361/392/56/
and
http://www.youreletters.com/t/52758/3785361/393/56/
Our Members Only service frequently referred to in the
e-Dispatch includes a subscription to TAIPAN, the monthly
communiqu� compiled by our Taipan Think Tank, as well as special
reports, rebates on conferences, and related information
services. For more information on how to enjoy full Membership
Privileges, please visit our home page:
http://www.youreletters.com/t/52758/3785361/394/56/
The Taipan Group's 247profits e-Dispatch is intended
specifically for mature investors with a strong sense of
individual responsibility who want to arbitrage different
viewpoints to optimize their personal investment strategy. We
reserve the right to remove readers we believe do not meet these
criteria from our distribution list without prior
notice.
You are welcome to distribute this message, at your discretion,
to others who you believe share the values of the Taipan Group.
NOTE TO OUR READERS: Taipan Group LLC or The Taipan Group's
247profits e-Dispatch does not act as an investment advisor or
advocate the purchase or sale of any security or investment.
Investments recommended in this publication should be made only
after consulting with your investment advisor and only after
reviewing the prospectus or financial statements of the company
in question.
Taipan Group LLC expressly forbids its writers from having a
financial interest in any security that they recommend to their
readers. Furthermore, all other employees and agents of Taipan
Group LLC and its affiliate companies must wait 24 hours before
following an initial recommendation published on the Internet,
or 72 hours after a printed publication is mailed.
*******
[EMAIL PROTECTED]
because you or someone using your e-mail address subscribed to
this service.
*******
To unsubscribe, Click the following link or copy and paste it
into your browser:
http://www.youreletters.com/u?id=3785361N&u=http://www.247profits.com&l=dispatch
------------------------ Yahoo! Groups Sponsor --------------------~-->
Make a clean sweep of pop-up ads. Yahoo! Companion Toolbar.
Now with Pop-Up Blocker. Get it for free!
http://us.click.yahoo.com/L5YrjA/eSIIAA/yQLSAA/BCfwlB/TM
--------------------------------------------------------------------~->
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/kumpulan/
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
